(Q64386942)
Statements
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer (English)
Lee M Krug
Jeffrey Crawford
David S Ettinger
Geoffrey I Shapiro
David Spigel
Tony Reiman
Jennifer S Temel
Glenn C Michelson
Donald Y Young
Daniel C Adelman